Pfizer, Inc. (NYSE:PFE) – Investment analysts at Jefferies Group reduced their FY2018 EPS estimates for shares of Pfizer in a research report issued to clients and investors on Thursday, according to Zacks Investment Research. Jefferies Group analyst J. Holford now forecasts that the biopharmaceutical company will earn $2.77 per share for the year, down from their prior forecast of $2.83. Jefferies Group currently has a “Neutral” rating and a $39.00 target price on the stock. Jefferies Group also issued estimates for Pfizer’s FY2019 earnings at $2.85 EPS, FY2020 earnings at $2.92 EPS and FY2021 earnings at $3.23 EPS.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The business’s revenue for the quarter was up .9% on a year-over-year basis. During the same period in the prior year, the company posted $0.61 EPS.
COPYRIGHT VIOLATION NOTICE: “Brokers Offer Predictions for Pfizer, Inc.’s FY2018 Earnings (NYSE:PFE)” was first published by Week Herald and is owned by of Week Herald. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://weekherald.com/2017/11/14/fy2018-eps-estimates-for-pfizer-inc-decreased-by-jefferies-group-pfe.html.
Several other analysts also recently issued reports on the stock. BMO Capital Markets reaffirmed a “buy” rating and issued a $39.00 price objective on shares of Pfizer in a research report on Friday. J P Morgan Chase & Co set a $39.00 target price on Pfizer and gave the company a “buy” rating in a research note on Wednesday, November 1st. Goldman Sachs Group, Inc. (The) set a $36.00 price objective on Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, November 1st. UBS AG set a $38.00 price objective on Pfizer and gave the stock a “buy” rating in a research note on Wednesday, November 1st. Finally, Berenberg Bank set a $36.00 price objective on Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, October 31st. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have assigned a buy rating to the company. Pfizer has an average rating of “Hold” and a consensus price target of $38.48.
Shares of Pfizer (NYSE:PFE) traded up $0.12 during mid-day trading on Monday, hitting $35.30. 23,788,100 shares of the stock traded hands, compared to its average volume of 20,377,111. The stock has a market cap of $210,220.00, a price-to-earnings ratio of 14.07, a P/E/G ratio of 2.49 and a beta of 1.01. Pfizer has a 1-year low of $30.51 and a 1-year high of $36.78. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43.
Several institutional investors have recently made changes to their positions in the company. Northstar Group Inc. lifted its holdings in shares of Pfizer by 0.4% during the 2nd quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 35 shares during the last quarter. Peregrine Asset Advisers Inc. raised its stake in shares of Pfizer by 0.5% in the 2nd quarter. Peregrine Asset Advisers Inc. now owns 7,354 shares of the biopharmaceutical company’s stock valued at $247,000 after acquiring an additional 35 shares in the last quarter. Northwest Quadrant Wealth Management LLC raised its stake in shares of Pfizer by 0.8% in the 2nd quarter. Northwest Quadrant Wealth Management LLC now owns 6,329 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 50 shares in the last quarter. River Wealth Advisors LLC raised its stake in shares of Pfizer by 0.3% in the 2nd quarter. River Wealth Advisors LLC now owns 15,818 shares of the biopharmaceutical company’s stock valued at $531,000 after acquiring an additional 55 shares in the last quarter. Finally, Meridian Wealth Management LLC raised its stake in shares of Pfizer by 0.5% in the 2nd quarter. Meridian Wealth Management LLC now owns 11,966 shares of the biopharmaceutical company’s stock valued at $402,000 after acquiring an additional 57 shares in the last quarter. Institutional investors and hedge funds own 69.36% of the company’s stock.
In other news, insider Alexander R. Mackenzie sold 7,350 shares of Pfizer stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $34.00, for a total transaction of $249,900.00. Following the completion of the sale, the insider now directly owns 132,124 shares in the company, valued at approximately $4,492,216. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Laurie J. Olson sold 8,064 shares of Pfizer stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $32.70, for a total value of $263,692.80. Following the sale, the insider now owns 74,506 shares of the company’s stock, valued at $2,436,346.20. The disclosure for this sale can be found here. Insiders sold a total of 374,621 shares of company stock worth $12,796,098 in the last three months. 0.06% of the stock is currently owned by company insiders.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Friday, November 10th will be paid a $0.32 dividend. The ex-dividend date is Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a yield of 3.63%. Pfizer’s dividend payout ratio is currently 78.53%.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.